An in situ Raman method was developed to characterize the disproportionation of two salts involving a complex polymorphic landscape comprising up to two metastable and one stable freebase forms. Few precedents exist for Raman calibration procedures for solid form quantitation involving more than two polymorphs, while no literature examples were found for cases with multiple metastable forms. Therefore, a new Raman calibration procedure was proposed by directly using disproportionation experiments to generate multiple calibration samples encompassing a range of polymorph ratios through in-line Raman measurements complemented by off-line reference X-ray diffraction measurements. The developed Raman methods were capable of accurately quantitating each solid form in situ when solid concentration variation was incorporated into the calibration dataset. The kinetic understanding of the thermodynamically driven polymorphic conversions gained from this Raman method guided the selection of the salt best suited for the delivery of the active ingredient in the drug product. This work provided a spectroscopic and mathematical approach for simultaneously quantitating multiple polymorphs from a complex mixture of solids with the objective of real-time monitoring.
Stochastic models and Monte Carlo (MC) simulations of content uniformity (CU) are powerful tools for assessing CU risk without extensive experimental effort. However, simulations are valuable only if they are accurate, used appropriately, and embedded within natural operational workflows. Toward these ends, we first analyze a stochastic model of tablet formation to develop simple quantitative characterizations of dose regimes based on the active pharmaceutical ingredient (API) particle size distribution (PSD) that provide early guidance on CU risk. Second, we study a MC simulation of the stochastic tablet formation model to validate the importance of selecting upper particle size cutoff diameters used in simulation based on manufacturing processes including a margin of safety. Finally, we demonstrate simulation-based PSD engineering and CU risk assessment tools for process chemists and formulators designed to fit into common workflows, such as early-stage guidance for PSD targets, predicting USP < 905 > pass rates and statistics, and exploring the API PSD parameters and dose strengths where CU risk is low.
10 August 2026 in International Journal of Pharmaceutics